On Friday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Winnebago Industries, Inc. (NYSE:WGO), Altera Corp. (NASDAQ:ALTR), Novogen Limited (NASDAQ:NVGN), Oxford Industries Inc. (NYSE:OXM)
Winnebago Industries, Inc. (NYSE:WGO), with shares gained 3.14%, closed at $21.03.
Altera Corp. (NASDAQ:ALTR), with shares jumped 28.39%, settled at $44.39, hitting new 52-week high of $45.00.
Novogen Limited (NASDAQ:NVGN), with shares climbed 21.01%, and closed at $4.55.
Oxford Industries Inc. (NYSE:OXM), surged 18.97%, and closed at $70.80.
Latest NEWS regarding these Stocks are depicted underneath:
Winnebago Industries, Inc. (NYSE:WGO)
Winnebago Industries, Inc. (WGO), has declared the appointment of William C. Fisher to an open seat on the Board of Directors. His term will start on May 1, 2015, and he will be placed on the Proxy in October for election by the shareholders in December to serve the remainder of the three year term.
Mr. Fisher was the Vice President and Chief Information Officer of Polaris Industries, Inc. from November 2007 until he stepped down on December 31, 2014. During his tenure at Polaris he also served as the Chief Information Officer and the General Manager of Service overseeing all technical, dealer, and consumer service operations. Preceding to joining Polaris, Mr. Fisher was employed by MTS Systems for 15 years in various positions in information services, software engineering, control product development, and general administration. Before that time, Mr. Fisher worked as a civil engineer for Anderson-Nichols and he later joined Autocon Industries, where he developed process control software.
Winnebago Industries, Inc. manufactures and sells recreation vehicles primarily for use in leisure travel and outdoor recreation activities. The corporation manufactures motor homes, which are self-propelled mobile dwellings that provide living accommodations and comprise kitchen, dining, sleeping, and bath areas, in addition to a lounge.
Altera Corp. (NASDAQ:ALTR)
Formerly on March 24, Altera Corp. (ALTR), and planned IP partner Eutecus declare the availability of the ReCo-Pro Multi-Channel High-Definition (HD) Video Analytics platform based on Eutecus’ MVE™ video and fusion analytics technology and Altera’s Cyclone® V SoC and Enpirion® PowerSoC devices.
Accessible from Eutecus, the ReCo platform has been chosen by Sensity Systems as the foundation for adding intelligent vision processing to its high-speed, Light Sensory Network (LSN), which is presently being installed in several US metropolitan areas. The Sensity open, multiservice NetSense platform enables industrial lighting owners and operators to reduce energy costs while offering advanced networked services for smart city applications, such as environmental and weather monitoring, parking administration, retail analytics and improved public safety.
The integration of Eutecus’ intelligent video and sensor analytics implemented on Altera FPGAs within the NetSense platform extends the capabilities of the applications, enabling greater operational awareness, effectiveness and security.
Altera Corporation, a semiconductor corporation, designs and sells programmable logic devices (PLDs), HardCopy application-specific integrated circuit (ASIC) devices, power system-on-chip devices (PowerSoCs), pre-defined design building blocks, and associated development tools.
Novogen Limited (NASDAQ:NVGN)
US-Australian drug discovery corporation, Novogen Limited (NVGN), and its partner, CanTx, Inc., and Yale University, on March 27 released pre-clinical data on experimental anti-cancer drug, Cantrixil. The data was presented as an oral presentation by Professor Gil Mor MD PhD of Yale Medical School to the 62nd Annual Scientific Meeting of the Society of Reproductive Investigation in San Francisco, CA.
In both in vitro and in animal studies, Cantrixil, has proved highly effective at killing human ovarian stem (tumor-initiating) cells, cells that otherwise are highly resistant to standard of care cytotoxic drugs and which generally are believed to be responsible for diseases recurrence following initial therapy. Researchers have been keen to understand how the active ingredient in Cantrixil, TRXE-002, is able to achieve this effect where other drugs have failed.
The data shows that Cantrixil specifically activates the JNK-Jun pathway leading to mitochondrial damage and the induction of genes associated with cell death (apoptosis). In addition, Cantrixil blocks the survival pathway pERK. The combination of these two cellular effects (down-regulation of pro-survival and up-regulation of pro-death pathways) provides a unique advantage to target chemo-resistant cancer stem cells.
Cantrixil is due to enter its first-in-man study in late-2015. The study will enroll patients with the terminal condition, malignant ascites, associated with late-stage abdominal carcinomatosis of various types of cancer, but mainly targeting ovarian cancer and colo-rectal cancer.
Novogen Limited is engaged in the pharmaceutical research and development business in Australia. The corporation has primarily two drug technology platforms, which comprise super-benzopyrans (SBPs) and anti-tropomyosins (ATMs).
Oxford Industries Inc. (NYSE:OXM)
Oxford Industries Inc. (OXM), declared financial results for its fourth quarter and 2014 fiscal year ended January 31, 2015. In the fourth quarter of fiscal 2014, merged net sales rose 10% to $274.5 million, as contrast to $250.4 million in the fourth quarter of fiscal 2013. Adjusted earnings per share for the quarter rose 21% to $1.08, surpassing guidance and as contrast to $0.89 in the same period last year. Fourth quarter GAAP earnings per share were $0.96 contrast to $0.91 in the same period of the preceding year.
For the full year of fiscal 2014, merged net sales rose 9% to $997.8 million from $917.1 million in fiscal 2013. Full-year adjusted earnings per share rose 6% to $2.98 for the 2014 fiscal year contrast to $2.81 in the preceding year. Full year GAAP earnings per share raised to $2.78 from $2.75 in the preceding year.
Thomas C. Chubb III, CEO and President commented, “Fiscal 2014 was another good year for Oxford capped by a strong fourth quarter performance driven by solid comparable store sales raises and improved gross margin. We have continued to leverage and reinforce the market leadership positions of each of our key lifestyle brands and were happy to see solid full-year performances from both Tommy Bahama and Lilly Pulitzer. These are foundational brands for Oxford that generate strong returns and have powerful, long-term growth opportunities.”
Oxford Industries, Inc., an apparel corporation, designs, sources, markets, and distributes apparel products of corporation-owned lifestyle brands, licensed, and private labels in the United States, the United Kingdom, rest of Europe, and internationally. It operates in four groups: Tommy Bahama, Lilly Pulitzer, Lanier Clothes, and Ben Sherman.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
